ArriVent BioPharma's shares plummeted nearly 47% after its China-licensed cancer drug failed a late-stage trial.
Shares of U.S. biopharmaceutical company ArriVent BioPharma plummeted nearly 47% on Tuesday after it reported that firmonertinib, a cancer treatment licensed from Shanghai Allist Pharmaceuticals in China, failed to meet its primary endpoint in a Phase 3 clinical trial. Analysts noted that this highlights the challenges Chinese biotech companies face in expanding into overseas markets. Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals for the treatment of non-small cell lung cancer, and ArriVent obtained exclusive development and commercialization rights for the drug outside of China in 2021.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Amazon fell 4.1% from its previous close, currently trading at $246.820.
-
2
Palantir closed down 6.63% from its previous close, currently trading at $143.490.
-
3
Silver prices pulled back to $41.103, touching a nearly 365-day low
-
4
The Russell 2000 Index fell 2.76% from its previous close, currently trading at 2,581.79.
-
5
Oracle is down 8.48% from its previous close, currently trading at $101.190.
-
6
Coinbase closed down 6.34% from its previous session, currently trading at $101.970.
-
7
MicroStrategy was down 9.67% from its previous close, currently trading at $77.80.
-
8
Gold fell 3.64% from its previous close, currently trading at $3,533.24.
-
9
Gold prices retreated to $3,533.24, hitting a nearly 365-day low.
-
10
Tesla closed 7.64% lower, currently trading at $345.820.
Markets Today
Recommended Reading


